Abstract: This disclosure relates to electrified vehicle charging systems that are equipped with multiple charging interfaces. An exemplary charging system may include a first charging interface, a second charging interface, an on-board charger module operably coupled to the first and second charging interfaces, and a control module configured to command the second charging interface to be isolated from the on-board charger module in response to a status change of a door of the first charging interface. The status of the door may be monitored by a sensor system of the charging system for determining whether or not to disable the second charging interface.

Abstract: This disclosure relates to electrified vehicle charging systems that are equipped with multiple charging interfaces. An exemplary charging system may include a first charging interface, a second charging interface, an on-board charger module operably coupled to the first and second charging interfaces, and a control module configured to command the second charging interface to be isolated from the on-board charger module in response to a status change of a door of the first charging interface. The status of the door may be monitored by a sensor system of the charging system for determining whether or not to disable the second charging interface.

Abstract: The present development is a reactor system for the production of nanostructures. The reactor system comprises a conical reactor body designed to maintain an upwardly directed vertical plasma flame and hydrocarbon flame. The reactor system further includes a metal powder feed that feeds into the plasma flame, a cyclone and a dust removal unit. The system is designed to produce up to 100 grams of metal oxide nanomaterials per minute.

Abstract: The present development is a reactor system for the production of nanostructures. The reactor system comprises a conical reactor body designed to maintain an upwardly directed vertical plasma flame and hydrocarbon flame. The reactor system further includes a metal powder feed that feeds into the plasma flame, a cyclone and a dust removal unit. The system is designed to produce up to 100 grams of metal oxide nanomaterials per minute.

Abstract: The present invention relates to a method of producing ultra-high melting point nonoxide ceramics with low porosity based on sintering at low temperatures of below about 1000° C. with low DC electric fields of less than about 100 V/cm.

Abstract: The present invention relates to a method of producing ultra-high melting point nonoxide ceramics with low porosity based on sintering at low temperatures of below about 1000° C. with low DC electric fields of less than about 100 V/cm.

Abstract: The present invention relates to synergistic combinations of the compounds of formula I such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and NSAIDs, in particular diclofenac, which have anti-tumour activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing said combinations.

Abstract: The present invention relates to synergistic combinations of the compounds of formula I such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and NSAIDs, in particular diclofenac, which have anti-tumor activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing said combinations.

Abstract: Entry of HIV-1 into target cells requires cell surface CD4 as well as additional host cell cofactors. A cofactor required for infection with virus adapted for growth in transformed T cell lines was recently identified and named fusin. Fusin, however, does not promote entry of macrophage-tropic viruses that are believed to be the key pathogenic strains in vivo. It has now been determined that the principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-tropic strains of HIV-1 is CC-CKR5, a receptor for the .beta.-chemokines RANTES, MIP-1.alpha., and MIP-1.beta.. It has also been found that individuals who are homozygous for a mutation of the CKR-5 receptor are resistent to HIV infection; in vitro infection requires a 1000-fold higher dose of HIV than normal cells. The mutation results in complete suppression of CKR-5 expression.